Equities analysts expect Trevena Inc (NASDAQ:TRVN) to report earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. Trevena posted earnings of ($0.10) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The business is expected to report its next earnings report on Wednesday, March 11th.
According to Zacks, analysts expect that Trevena will report full-year earnings of ($0.28) per share for the current financial year. For the next fiscal year, analysts expect that the business will report earnings of ($0.34) per share. Zacks’ EPS calculations are an average based on a survey of research firms that follow Trevena.
Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01).
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Trevena by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock worth $4,032,000 after buying an additional 403,060 shares in the last quarter. BlackRock Inc. raised its stake in shares of Trevena by 1.9% in the second quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock worth $2,727,000 after purchasing an additional 49,900 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Trevena by 50.2% in the second quarter. Renaissance Technologies LLC now owns 1,928,850 shares of the biopharmaceutical company’s stock worth $1,987,000 after purchasing an additional 644,812 shares during the last quarter. Morgan Stanley raised its stake in shares of Trevena by 2,651.1% in the second quarter. Morgan Stanley now owns 530,436 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 511,155 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Trevena in the second quarter worth about $264,000. 23.72% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:TRVN traded down $0.04 during midday trading on Monday, hitting $0.63. 31,886 shares of the company traded hands, compared to its average volume of 1,587,975. The firm’s fifty day moving average is $0.89 and its 200-day moving average is $1.01. Trevena has a 12-month low of $0.38 and a 12-month high of $2.00. The firm has a market capitalization of $66.67 million, a P/E ratio of -1.52 and a beta of 2.63. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of 0.23.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: Understanding Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.